multinational companies

Subscribe to multinational companies

By King & Wood Mallesons’ International Dispute Resolution Group

In recent years, several large multinational pharmaceutical companies have been found to be in violation of the Anti-Unfair Competition Law. Compliance in the area of commercial bribery is increasingly a focus of the Chinese authorities. Most recently, pharmaceutical companies have been punished in China for commercial bribery. Not only the companies, but also individual employees who have violated Chinese law, are being charged and prosecuted.

The State Administration of Industry and Commerce, as well as the administrative agencies of industry and commerce at lower levels, are primarily responsible for the enforcement of the anti-commercial bribery laws. The focus has been enforcement of the Anti-Unfair Competition Law and the Interim Provisions on Prohibition of Commercial Bribery (“Interim Provisions”).
Continue Reading China Focuses on Bribery and Corruption in Multinational Companies

By Denning Jin    King & Wood Mallesons’ IP Litigation Group

Introduction

With the China (Shanghai) Pilot Free Trade Zone Arbitration Rules that came into effect on May 1, 2014 (“FTZ Arbitration Rules”), the Shanghai International Arbitration Center (“SHIAC”) adopts practices of the most renowned international arbitration institutions, and follows trends and developments in international commercial arbitration. The FTZ Arbitration Rules do not only apply to cases related to the China (Shanghai) Free Trade Zone (“FTZ”), they may also apply to cases where parties have agreed to apply the FTZ Arbitration Rules, regardless of the nature of the dispute.
Continue Reading What Will the New Developments in the FTZ Arbitration Rules on Interim Measures and Evidence Rules Mean for Multinational Companies?